Core Value
Research in age-related diseases
EyeGene, Inc. ‘s Corporate Identity (CI) stems from a composition of “EYE” and “Genome”. As these words convey, EyeGene, since its establishment, has focused on discovering the secrets behind ocular diseases and developing therapeutics based on our expertise in Proteomics and Immunology. Further, we are continuously striving in Research & Development of innovative new biological drugs for the treatment of aging-related degenerative diseases through technology obtained from research in the field of genomic and proteomic informatics.
Wide NETWORK
EyeGene has established a network through strong alliances with University Hospitals. Further networks have been established with Yonsei University’s proteomics research laboratory, Yonsei University Medical Center’s Cardiovascular Product Evaluation Center, Sejong University’s department of pharmacology, and Korea Advanced Institute of Science and Technology. R&D is continuously progressing after the collaboration and license agreement with Huons for EG-Decorin (therapeutic for pressure ulcers), and EyeGene has established a wide network of working relationships not only on the domestic front with biotech companies such as N cbit and GeneMatrix, but also on globally with research institutes and CROs such as Ora, Optimed, Harlan and Comparative biosciences.
EyeGene Logo
EyeGene, Inc. ‘s Corporate Identity (CI) stems from a composition of “EYE” and “Genome”.